Breast Imaging Research Group
University of Dundee
Mailbox 4, Level 7
Ninewells Hospital & Medical School
+(44) 01382 383967
Kulsam’s expertise is in clinical trial management. Prior to joining the University of Dundee, Kulsam worked at the Cancer Research UK & University College London Cancer Trials Centre in London, where she managed multi-centre randomised controlled trials.
2004: PhD Biology – University College London
1998: MSc Industrial Biotechnology – Liverpool John Moores University
1997: BSc (Hons) Biochemistry – University of Liverpool
Kulsam is responsible for the management of the Digital Breast Tomosynthesis (DBT) Study in Younger Symptomatic Women (Chief Investigator: Prof Andy Evans). This is a multi-centre study which has recruited 446 patients from across the UK. The primary objective of the study is to determine whether DBT is more sensitive than standard digital mammography for the detection of malignancy in symptomatic women aged under 60 with clinical and/or ultrasound features suggestive of malignancy. This research will help to establish whether the newly developed DBT technology has a role in routine clinical practice.
Lee, SM., Woll, PJ., Rudd, R., Ferry, D., O’Brien, M., Middleton, G., Spiro, SG., James, L., Ali, K., Jitlal, M. and Hackshaw, A. (2009). Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute: 101, 1049-1057.
Lee, SM., Woll, PJ., James, LE., Hatton, M., Ali, K., Spiro, SG., Ali, SR. and Hackshaw, A. (2007). A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC): PRS-04. Journal of Thoracic Oncology: 2(8), S306-S307.
Lee, SM., Woll, PJ., Rudd, RM.; Gower, NH., Ottensmeier, CH., Ali, K; Spiro, SG. and Hackshaw, A. (2007). A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC): C1-O3. Journal of Thoracic Oncology: 2(8), S359-S359.
Partridge, M., Brakenhoff, R., Phillips, E., Ali, K., Francis, R., Hooper, R., Lavery, K., Brown, A. and Langdon, J. (2003). Detection of rare disseminated tumour cells identifies head and neck cancer patients at risk of treatment failure. Clinical Cancer Research: 9, 5287-5294.